Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial

Background: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PA...

Descripción completa

Detalles Bibliográficos
Autores: Vachiéry, Jean-Luc, Galiè, Nazzareno, Barberà i Mir, Joan Albert, Frost, Adaani E., Ghofrani, Hossein-Ardeschir, Hoeper, Marius M, McLaughlin, Vallerie V., Peacock, Andrew J., Simonneau, Gérald, Blair, Christiana, Miller, Karen L., Langley, Jonathan, Rubin, Lewis J., AMBITION Investigators
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/183972
Acceso en línea:https://hdl.handle.net/2445/183972
Access Level:acceso abierto
Palabra clave:Hipertensió pulmonar
Vasodilatadors
Pulmonary hypertension
Vasodilators
id ES_bc22f3a0c9e38f3075ffd413a09c3e52
oai_identifier_str oai:diposit.ub.edu:2445/183972
network_acronym_str ES
network_name_str España
repository_id_str
spelling Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trialVachiéry, Jean-LucGaliè, NazzarenoBarberà i Mir, Joan AlbertFrost, Adaani E.Ghofrani, Hossein-ArdeschirHoeper, Marius MMcLaughlin, Vallerie V.Peacock, Andrew J.Simonneau, GéraldBlair, ChristianaMiller, Karen L.Langley, JonathanRubin, Lewis J.AMBITION InvestigatorsHipertensió pulmonarVasodilatadorsPulmonary hypertensionVasodilatorsBackground: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) vs pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination therapy group, although a significant effect was not observed in a post-hoc analysis of all-cause hospitalization. Methods: The effect of initial combination therapy with ambrisentan and tadalafil in AMBITION was further explored to study PAH-related hospitalization, which was not reported in the primary publication. Results: Initial combination therapy was associated with a 63% reduction in risk of PAH-related hospitalization when compared with pooled monotherapy (hazard ratio [HR] 0.372, 95% confidence interval [CI] 0.217 to 0.639, p = 0.0002). For every 9 patients treated with combination therapy vs monotherapy, 1 PAH-related hospitalization could be prevented over a 1-year period. Serious adverse events leading to hospitalization, not necessarily PAH-related, occurred in 87 of 253 (34%) and 89 of 247 (36%) of patients on combination therapy and pooled monotherapy, respectively (post-hoc summary). Conclusions: Initial combination therapy with ambrisentan and tadalafil was found to reduce the risk of PAH-related hospitalization by 63% compared with pooled monotherapy.Elsevier2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/183972Articles publicats en revistes (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.healun.2018.11.006Journal of Heart and Lung Transplantation, 2019, vol. 38, num. 2, p. 194-202https://doi.org/10.1016/j.healun.2018.11.006cc-by-nc-nd (c) Elsevier, 2019https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1839722026-05-27T06:46:51Z
dc.title.none.fl_str_mv Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
title Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
spellingShingle Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
Vachiéry, Jean-Luc
Hipertensió pulmonar
Vasodilatadors
Pulmonary hypertension
Vasodilators
title_short Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
title_full Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
title_fullStr Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
title_full_unstemmed Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
title_sort Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
dc.creator.none.fl_str_mv Vachiéry, Jean-Luc
Galiè, Nazzareno
Barberà i Mir, Joan Albert
Frost, Adaani E.
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M
McLaughlin, Vallerie V.
Peacock, Andrew J.
Simonneau, Gérald
Blair, Christiana
Miller, Karen L.
Langley, Jonathan
Rubin, Lewis J.
AMBITION Investigators
author Vachiéry, Jean-Luc
author_facet Vachiéry, Jean-Luc
Galiè, Nazzareno
Barberà i Mir, Joan Albert
Frost, Adaani E.
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M
McLaughlin, Vallerie V.
Peacock, Andrew J.
Simonneau, Gérald
Blair, Christiana
Miller, Karen L.
Langley, Jonathan
Rubin, Lewis J.
AMBITION Investigators
author_role author
author2 Galiè, Nazzareno
Barberà i Mir, Joan Albert
Frost, Adaani E.
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M
McLaughlin, Vallerie V.
Peacock, Andrew J.
Simonneau, Gérald
Blair, Christiana
Miller, Karen L.
Langley, Jonathan
Rubin, Lewis J.
AMBITION Investigators
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hipertensió pulmonar
Vasodilatadors
Pulmonary hypertension
Vasodilators
topic Hipertensió pulmonar
Vasodilatadors
Pulmonary hypertension
Vasodilators
description Background: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) vs pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination therapy group, although a significant effect was not observed in a post-hoc analysis of all-cause hospitalization. Methods: The effect of initial combination therapy with ambrisentan and tadalafil in AMBITION was further explored to study PAH-related hospitalization, which was not reported in the primary publication. Results: Initial combination therapy was associated with a 63% reduction in risk of PAH-related hospitalization when compared with pooled monotherapy (hazard ratio [HR] 0.372, 95% confidence interval [CI] 0.217 to 0.639, p = 0.0002). For every 9 patients treated with combination therapy vs monotherapy, 1 PAH-related hospitalization could be prevented over a 1-year period. Serious adverse events leading to hospitalization, not necessarily PAH-related, occurred in 87 of 253 (34%) and 89 of 247 (36%) of patients on combination therapy and pooled monotherapy, respectively (post-hoc summary). Conclusions: Initial combination therapy with ambrisentan and tadalafil was found to reduce the risk of PAH-related hospitalization by 63% compared with pooled monotherapy.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/183972
url https://hdl.handle.net/2445/183972
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.healun.2018.11.006
Journal of Heart and Lung Transplantation, 2019, vol. 38, num. 2, p. 194-202
https://doi.org/10.1016/j.healun.2018.11.006
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Elsevier, 2019
https://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Elsevier, 2019
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Articles publicats en revistes (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418087086817280
score 15,300719

Similares en LA Referencia